Anavex to Present at Neuroscience 2012 in New Orleans
Vancouver, BC — October 12, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) announces that new data on ANAVEX 2-73 will be presented in a poster session at Neuroscience 2012 in New Orleans. ANAVEX 2-73 is the company’s lead compound for Alzheimer’s disease currently in human clinical trials. Presentation details are as follows: Date: Wednesday, October…